GlassScriptPhysician profile
Victor Guardiola Amado
NPI 1750583803
$1,385.65
in general payments reported to CMS, 2019-2025
18 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.05 · 2021: $11.92 · 2022: $212 · 2023: $569 · 2024: $354 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.14 |
| Education | $109.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $238.82 | 2022-2025 | Monoferric |
| Daiichi Sankyo INC. | $187.98 | 2022-2024 | Enhertu, Injectafer |
| Incyte Corporation | $142.47 | 2022-2023 | Jakafi |
| Merck Sharp & Dohme LLC | $129.37 | 2022-2025 | Keytruda, Lynparza |
| Sobi, INC | $113.29 | 2022-2025 | |
| Lilly USA, LLC | $93.57 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $86.20 | 2023-2024 | |
| Gilead Sciences, INC. | $79.78 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $68.08 | 2023-2024 | Rezlidhia, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $46.19 | 2023-2025 | Enhertu |
| Puma Biotechnology, INC. | $35.37 | 2024-2025 | |
| Encore Medical, LP | $30.05 | 2020 | |
| Genzyme Corporation | $26.99 | 2023 | |
| Eisai INC. | $24.48 | 2024 | |
| Pfizer INC. | $23.78 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $21.61 | 2024 | Besremi |
| Csl Behring | $20.21 | 2023 | Idelvion |
| Agios Pharmaceuticals, INC. | $17.41 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Guardiola Amado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.